17 · Sources

Sources

Erasca says 44% of 25 responded; it’s Phase 1 · No. 052 · · About 1 min read

Bookmarks need a Mind Club sign-in. How sign-in works

Sources across your briefs

  1. Company releases and filings: Erasca, Revolution Medicines, Merck, Actinogen, Alnylam, Celldex, BioVersys, SELLAS, Humacyte, Capricor, BridgeBio, Vertex, Cogent, Gilead, Praxis (11.19 and 11.20, with earlier releases for calendar dates) Co
  2. Robinhood market data (11.19 closes); U.S. Treasury daily par yield curve (opens another website in a new tab); FOMC statement (10.28) (opens another website in a new tab) Data Gov
  3. ClinicalTrials.gov: NCT06983743 (opens another website in a new tab), NCT06445062 (opens another website in a new tab), NCT06125951 (opens another website in a new tab), NCT06727552 (opens another website in a new tab), NCT06748937 (opens another website in a new tab), NCT06114628 (opens another website in a new tab), the 70-trial watchlist and the KRAS trial search for the card Reg
  4. NEJM, Nature, Science, Cell and Nature Medicine papers via PubMed Peer
  5. Open Targets, ChEMBL and Drugs@FDA for the Target Evidence Card Data Gov
  6. CMS negotiated prices page; Federal Reserve FOMC calendar Gov
  7. BioSpace, PharmExec, GeneOnline, Pharmaceutical Technology, STAT, Healio, Biotech Dispatch, Investing News, Yahoo Finance, OncLive, StockTitan, The Weekend Spread, CappNotes, Renaissance Capital; BioBucks, Panabee Press Data

Every source above was opened by the run that built this edition or its research lanes, except where an item says a release did not load. Where we read a release through a mirror, the item says so.